NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

副甲狀腺機能亢進症 (HPT),高磷酸鹽血症 (HP),含高鉀血症 (HK) 的慢性腎臟病 (CKD) :至2030年的流行病學預測

Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030

出版商 GlobalData 商品編碼 1005541
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
副甲狀腺機能亢進症 (HPT),高磷酸鹽血症 (HP),含高鉀血症 (HK) 的慢性腎臟病 (CKD) :至2030年的流行病學預測 Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030
出版日期: 2021年04月30日內容資訊: 英文 48 Pages
簡介

慢性腎臟病(CKD)或慢性腎臟病,是特徵為隨時間流逝慢慢腎功能降低的狀態。初期階段,CKD幾乎是無症狀的狀態,給予腎臟損傷,隨時間經過導致腎功能喪失,隨著病情進行中,症狀惡化,最終達到腎功能衰竭。

在7個主要市場(美國,法國,德國,義大利,西班牙,英國以及日本)中,CKD的確診病例數,預計以年度成長率(AGR)1.01%擴大,從2020年的856萬9,869案例到2030年增加到944萬881案例。在2030年的7個主要市場中美國確診的盛行率最高為425萬3,149案例,義大利33萬9,208案例最少。確診的盛行率和CKD的盛行率持續增加,認為是依據各市場人口動態。

本報告提供副甲狀腺機能亢進症(HPT),高磷酸鹽血症(HP),含高鉀血症(HK)的慢性腎臟病(CKD)的相關調查,提供7個主要市場(美國,法國,德國,義大利,西班牙,英國以及日本)趨勢,CKD的風險要素,合併症,全球流行病學趨勢及預測等資訊。

目錄

目錄

第1章 CKD-副甲狀腺機能亢進症,高磷酸鹽血症,高鉀血症:摘要整理

  • 催化劑
  • 相關報告
  • 今後的報告

第2章 流行病學

  • 病歷
  • 危險因素和合併症
  • 世界及過去趨勢
  • 7個主要市場預測調查手法
    • 資訊來源
    • 預測的前提條件與方法
    • 預測的前提條件與方法:CKD的診斷病例數-7個主要市場
    • 預測的前提條件與方法:CKD的整體病例數
    • 預測的前提條件與方法:各階段CKD的診斷和病例的總合
    • 透析成癮為基礎CKD診斷病例數
    • 透析依賴性及非依賴性CKD病例的副甲狀腺機能亢進症伴隨的CKD的診斷病例數
    • 透析依賴性及非透析依賴性CKD病例的高磷酸鹽血症伴隨的CKD的診斷病例數
    • 透析依賴性及非透析性CKD病例的量鉀血症伴隨的CKD的診斷病例數
  • 慢性腎臟病的流行病學預測副甲狀腺機能亢進症,高磷酸鹽血症,高鉀血症(2020-2030)
    • CKD的一般診斷病例數
    • 各年齡:CKD診斷病例數
    • 性別:CKD診斷病例數
    • 各階段:CKD診斷病例數
    • 透析成癮為基礎CKD診斷病例數
    • 透析依賴性及非透析性CKD病例的副甲狀腺機能亢進症伴隨的CKD診斷病例數
    • 透析依賴性及非依賴性CKD病例的高磷酸鹽血症伴隨的CKD診斷病例數
    • 透析依賴性及非依賴性CKD病例的量鉀血症伴隨的CCKD診斷病例數
    • CKD總病例數
    • 各年齡:CKD總病例數
    • 性別:CKD總病例數
    • 各階段:CKD總病例數
  • 討論
    • 流行病學預測的洞察
    • COVID-19的影響
    • 分析的限制
    • 分析的優勢

第3章 附錄

  • 書志
  • 關於作者
    • 流行病學者
    • 評論者
    • 治療分析及流行病學的全球董事
    • 醫療保健營運及策略的全球主要及EVP
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER271-21

Chronic kidney disease (CKD), or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. In the early stages, CKD is a largely asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time (Centers for Disease Control and Prevention, 2019). As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2019). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered as the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013).

In the 7MM, the diagnosed prevalent cases of CKD are expected to increase from 8,569,869 cases in 2020 to 9,440,881 cases in 2030, at an Annual Growth Rate (AGR) of 1.01%. In 2030, the US will have the highest number of diagnosed prevalent cases of CKD in the 7MM, with 4,253,149 diagnosed prevalent cases, whereas Italy will have the fewest diagnosed prevalent cases with 339,208 cases. In the 7MM, the total prevalent cases of CKD are expected to increase from 97,176,505 cases in 2020 to 107,283,608 cases in 2030, at an AGR of 1.04%. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases and total prevalent cases of CKD to population dynamics in each market.

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed and total prevalent cases of CKD. The diagnosed and total prevalent cases of CKD are segmented by age (18 years and older), sex, and stage. The diagnosed prevalent cases of CKD are segmented based on dialysis-dependent and non-dialysis-dependent cases.
  • The dialysis dependent cases are further segmented by hemodialysis-dependent and peritoneal dialysis-dependent. Additionally, the diagnosed prevalent cases of CKD were further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases. This epidemiology forecast for CKD is supported by data obtained from peer-reviewed articles and population-based studies.
  • The CKD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The CKD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CKD market.
  • Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for CKD therapeutics in each of the markets covered.
  • Understand magnitude of CKD by stage, hemodialysis-dependent and peritoneal dialysis-dependent; hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases of CKD.

Table of Contents

Table of Contents

1 CKD - Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 7MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CKD - 7MM
    • 2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of CKD
    • 2.4.5 Forecast Assumptions and Methods: Diagnosed and Total Prevalent Cases of CKD by Stage
    • 2.4.6 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
    • 2.4.7 Diagnosed Prevalent Cases of CKD with Hyperparathyroidism Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
    • 2.4.8 Diagnosed Prevalent Cases of CKD with Hyperphosphatemia Among Dialysis Dependent and Non-dialysis Dependent CKD Cases
    • 2.4.9 Diagnosed Prevalent Cases of CKD with Diagnosed Prevalent Cases of CKD with Hyperkalemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
  • 2.5 Epidemiological Forecast for Chronic Kidney Disease Hyperparathyroidism, Hyperphosphatemia and Hyperkalemia (2020-2030)
    • 2.5.1 Diagnosed Prevalent Cases of CKD
    • 2.5.2 Age-Specific Diagnosed Prevalent Cases of CKD
    • 2.5.3 Sex-Specific Diagnosed Prevalent Cases of CKD
    • 2.5.4 Diagnosed Prevalent Cases of CKD by Stage
    • 2.5.5 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
    • 2.5.6 Diagnosed Prevalent Cases of CKD with Hyperparathyroidism Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases
    • 2.5.7 Diagnosed Prevalent Cases of CKD with Hyperphosphatemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
    • 2.5.8 Diagnosed Prevalent Cases of CKD With Hyperkalemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
    • 2.5.9 Total Prevalent Cases of CKD
    • 2.5.10 Age-Specific Total Prevalent Cases of CKD
    • 2.5.11 Sex-Specific Total Prevalent Cases of CKD
    • 2.5.12 Total Prevalent Cases of CKD by Stage
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: KDIGO Classification of CKD
  • Table 4: Risk Factors and Comorbidities for CKD

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of CKD, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 2: 7MM, Total Prevalent Cases of CKD, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 3: 7MM, Diagnosed Prevalence of CKD, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 4: 7MM, Total Prevalence of CKD, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed and Total Prevalent Cases of CKD by Stage
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD with Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases
  • Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of CKD
  • Figure 10: 7MM, Diagnosed Prevalent Cases of CKD, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 11: 7MM, Diagnosed Prevalent Cases of CKD by Age, N, Both Sexes, 2020
  • Figure 12: 7MM, Diagnosed Prevalent Cases of CKD by Sex, N, Ages ≥18 Years, 2020
  • Figure 13: 7MM, Diagnosed Prevalent Cases of CKD by Stage, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 14: 7MM, Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 15: 7MM, Diagnosed Prevalent Cases of CKD with Hyperparathyroidism, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 16: 7MM, Diagnosed Prevalent Cases of CKD With Hyperphosphatemia, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 17: 7MM, Diagnosed Prevalent Cases of CKD with Hyperkalemia, N, Both Sexes, ≥18 Years, 2020
  • Figure 18: 7MM, Total Prevalent Cases of CKD, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 19: 7MM, Diagnosed Total Cases of CKD by Age, N, Both Sexes, 2020
  • Figure 20: 7MM, Total Prevalent Cases of CKD by Sex, N, Ages ≥18 Years, 2020
  • Figure 21: 7MM, Total Prevalent Cases of CKD by Stage, N, Both Sexes, Ages ≥18 Years, 2020